Lupin gets USFDA nod for generic version of Prozac tablets to treat depressive disorder

Published On 2019-08-17 04:15 GMT   |   Update On 2021-08-16 07:28 GMT

The company has received approval for Fluoxetine Tablets from the US Food and Drug Administration(USFDA) to market its product which is a generic version of Eli Lilly and Company's Prozac tablets, Lupin said in a statement.


New Delhi: Drug maker Lupin Tuesday said it has received approval from the US health regulator to market Fluoxetine Tablets, used to treat a major depressive disorder, in the American market.


The company has received approval from the US Food and Drug Administration(USFDA) to market its product which is a generic version of Eli Lilly and Company's Prozac tablets, Lupin said in a statement.


Read Also: USFDA completes inspection of Nagpur facility with no observations: Lupin


The product is also indicated for the treatment of an obsessive-compulsive disorder, Bulimia Nervosa and panic disorder, it said.


Headquartered in Mumbai, Lupin's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. The company was founded in 1968 by Desh Bandhu Gupta, who was a professor of chemistry at BITS-Pilani, Rajasthan.


Read Also: Lupin gets EIR from USFDA for Oral Dosage facility in Aurangabad

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News